Skip to content

Prospective Interventional Study on Ovarian Function Preservation by Endometrioma Ablation Using the Thulium YAG Laser

Prospective Interventional Study on Ovarian Function Preservation by Endometrioma Ablation Using the Thulium YAG Laser

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1052230182
Enrollment
10
Registered
2024-02-15
Start date
2024-02-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Endometrioma ovarian endometrioma, infertility

Interventions

Cystectomy is performed for endometrioma with the desire to fertility. Cystectomy improves the natural pregnancy rate but does not improve the pregnancy rate in assisted reproductive technology. Ablat

Sponsors

Kawahara Naoki
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Patients with endometrioma who have been diagnosed as infertile, for whom surgery is indicated and for whom infertility treatment is covered by insurance. 1) Patients scheduled for abdominal or laparoscopic surgery 2) premenopausal women 3) Between 20 and 43 years of age at the time of consent. 4) The patient has the capacity to consent and is able to give written consent of her own free will. 5) ECOG-PS1 or lower. (ECOG-PS1 means that the patient is limited in strenuous activities, but can walk and perform light or sedentary tasks.) Patients who are eligible for surgery and whose postoperative infertility treatment is covered by insurance are selected.

Exclusion criteria

Exclusion criteria: Exclude those that are known to affect serum AMH levels. 1) Those who have used sex hormones within 4 weeks prior to obtaining consent 2) Those with a history of surgery for endometriosis 3) Who have been diagnosed with a malignant tumor 4) Pregnant women or those who may be pregnant or breastfeeding 5) Patients who are judged by the principal investigator and subinvestigators to be unsuitable for this study.

Design outcomes

Primary

MeasureTime frame
Change in serum AMH

Secondary

MeasureTime frame
Serum CA125 changes, ablation depth, surgical outcomes, recurrence rates, and pregnancy rates

Contacts

Public ContactMotoki Matsuoka

Nara Medical University

k162772@naramed-u.ac.jp+81-744-22-3051

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026